rtkn2 Antibody

What is the optimal dilution range for RTKN2 antibodies in different applications?

RTKN2 antibodies require specific dilution ratios depending on the application:

These ranges should be considered starting points for optimization. For Western blotting applications, polyclonal antibodies like ABIN2579754 (targeting AA 99-127) work effectively at 1:100-1:500 dilutions . The appropriate dilution is highly dependent on sample type, with antibodies performing differently across human, mouse, and rat tissues. Always validate in your specific experimental system as some RTKN2 antibodies show stronger reactivity in specific cell lines (HL-60, Raji, HEK-293) .

Which cellular components and tissues show the highest RTKN2 expression?

RTKN2 exhibits distinctive expression patterns:

• Cell Types: Highest expression in lymphocytes, particularly CD4+ T-cells compared to CD8+ cells . It's also expressed in bone marrow-derived cells .

• Developmental Stages: In mice thymic subsets, RTKN2 is approximately 10-14 fold higher in immature double negative (CD4-/CD8-) and double positive (CD4+/CD8+) populations than in mature single positive T-cells .

• Regulation: RTKN2 is markedly down-regulated following T-cell receptor activation by phytohemagglutinin (PHA) or anti-CD3 .

• Tissues: RTKN2 antibodies have been validated to detect the protein in human testis, brain, placenta, and skin tissues .

• Cell Lines: RTKN2 protein can be readily detected in HL-60 cells, Raji cells, HEK-293 cells, and mouse lymph tissue .

When designing tissue-specific studies, select antibodies with demonstrated reactivity in your tissue of interest, as expression levels vary significantly.

How can I validate the specificity of my RTKN2 antibody?

A comprehensive validation strategy should include:

• Positive and negative controls: Use cell lines with known RTKN2 expression levels. HEK-293 cells express low endogenous RTKN2, making them suitable for negative controls or overexpression studies . CD4+ T-cells serve as excellent positive controls.

• Protein overexpression: Transfect cells with RTKN2 expression vectors. The observed increase in signal at the expected molecular weight (69 kDa for the canonical form) validates antibody specificity .

• Knockdown verification: Implement RTKN2 knockdown using shRNA or siRNA. Studies have used specific sequences targeting RTKN2 (e.g., siRNA3 as reported in research) that produce consistent knockdown efficiency . The corresponding decrease in signal confirms specificity.

• Peptide competition: Pre-incubate the antibody with the immunogen peptide before application to verify binding specificity. For example, with antibodies generated against KLH-conjugated peptides between amino acids 99-127 .

• Multiple antibody comparison: Use antibodies targeting different epitopes of RTKN2 to confirm consistent detection patterns.

• Mass spectrometry: For definitive validation, immunoprecipitate RTKN2 and verify the protein identity by mass spectrometry.

How should I design experiments to address conflicting findings regarding RTKN2's role in cancer?

The literature shows contradictory findings about RTKN2 in cancer, particularly in lung cancer:

To address these contradictions:

• Cell-type specific analysis: RTKN2 may function differently across cancer subtypes. Use multiple cell lines representing different molecular subtypes of your cancer model.

• Comprehensive pathway analysis: Simultaneously examine multiple signaling pathways. Research shows RTKN2 affects both NF-κB and Wnt/β-catenin pathways.

• Use genetic manipulation with phenotypic assays: Implement both knockdown and overexpression systems:

  • For knockdown, effective shRNA sequences have been documented (e.g., sh-RTKN2 #1 and #2)

  • Measure multiple functional endpoints (proliferation, apoptosis, migration, invasion)

• Analyze microenvironmental factors: The contradictory findings may reflect interactions with tumor microenvironment. Consider co-culture experiments or in vivo models.

• Examine isoform-specific effects: The three reported RTKN2 isoforms may have distinct functions . Design primers and antibodies to distinguish between isoforms.

A well-designed experiment might include knockdown and overexpression of RTKN2 in multiple cell lines, followed by comprehensive phenotypic assays and analysis of both NF-κB and Wnt/β-catenin pathway components.

What are the optimal experimental approaches to study RTKN2's role in apoptotic pathways?

RTKN2 has been linked to resistance against intrinsic apoptosis through NF-κB signaling. To investigate this:

• Select appropriate apoptotic inducers: Use agents that specifically target the intrinsic pathway:

  • 25-hydroxy cholesterol (25-OHC): Operates through BCL-2 downregulation

  • Camptothecin: Topo-isomerase inhibitor that activates the intrinsic pathway

  • Avoid extrinsic pathway inducers like TNFα, as RTKN2 shows pathway specificity

• Measure comprehensive apoptotic markers:

  • Track expression of multiple BCL-2 family members (Bax, Bim, BCL-2)

  • Monitor mitochondrial membrane potential using JC-1 or TMRE staining

  • Assess caspase activation, particularly caspase-9 (intrinsic) vs caspase-8 (extrinsic)

  • Use Annexin V/PI staining for early/late apoptosis discrimination

• Apply pathway inhibitors: Use NF-κB inhibitors (e.g., bortezomib at 0.6 nM for 24 hours) to determine if RTKN2's anti-apoptotic effects are NF-κB dependent .

• Design time-course experiments: Monitor BCL-2 family gene expression changes over 6 days as documented in previous studies .

• Combine with GTPase interaction studies: Though RTKN2 doesn't appear to bind RhoA or Rac2 directly in some studies , investigate potential interactions with other GTPases using co-immunoprecipitation approaches.

For optimal results, compare RTKN2 overexpression and knockdown effects in the same experimental system, and include both cancer and normal cell models to determine context-dependent functions.

How can RTKN2 antibodies be optimized for detecting protein-protein interactions in immune cells?

RTKN2's high expression in immune cells makes interaction studies particularly relevant, but requires optimization:

• Antibody selection criteria:

  • Choose antibodies validated for immunoprecipitation applications

  • Select clones targeting regions outside predicted protein-protein interaction domains

  • For Co-IP applications, prefer antibodies with minimal cross-reactivity

• Cell system considerations:

  • Primary CD4+ T-cells are ideal but challenging; nucleofection has proven effective for transfection

  • Compare resting and activated T-cells, as RTKN2 expression decreases after TCR activation

  • Consider using Jurkat cells as a more tractable model system

• Technical optimization steps:

  • Cross-linking: Optimize formaldehyde concentration (0.1-1%) and time (5-20 minutes)

  • Lysis conditions: Test different buffers (RIPA versus milder NP-40 or digitonin-based)

  • Pre-clearing strategies: Implement to reduce non-specific binding

  • Washing stringency: Balance between preserving interactions and reducing background

• Confirmation approaches:

  • Reciprocal Co-IP (pull down with antibody against interaction partner)

  • Proximity ligation assay as an in situ alternative

  • FRET or BiFC for live-cell interaction studies

While classic studies showed RTKN2 doesn't interact with RhoA or Rac2 , recent evidence suggests it may interact with other signaling molecules in the Wnt/β-catenin pathway . Design your experiments to capture these novel interactions using antibodies directed against different epitopes.

What methodological approaches should be used when studying RTKN2 in glycolysis and metabolic regulation?

Recent research has revealed RTKN2's involvement in cellular metabolism, particularly glycolysis in cancer cells . To investigate this function:

• Metabolic parameter measurements:

  • Oxygen Consumption Rate (OCR): Measure using Seahorse XF analyzers or similar technology

  • Extracellular Acidification Rate (ECAR): Quantify as an indicator of glycolytic activity

  • Track steady-state glycolytic flux and glycolytic capacity following RTKN2 manipulation

• Key experimental controls:

  • Compare RTKN2 knockdown effects with known glycolysis modulators

  • Include metabolic inhibitors (2-DG for glycolysis, oligomycin for OXPHOS)

  • Account for cell proliferation differences when interpreting metabolic data

• Pathway analysis integration:

  • Examine NF-κB pathway components in parallel with metabolic measurements

  • Consider connections between RTKN2, metabolism, and the tumor microenvironment

  • Investigate downstream metabolic enzymes (HK2, PKM2, LDHA) by Western blot

• Technical considerations:

  • Standardize cell density and growth conditions prior to metabolic measurements

  • Use consistent media composition across experimental groups

  • Implement both gain and loss of function approaches (RTKN2 overexpression and knockdown)

Research has shown that RTKN2 knockdown prominently reduces OCR and enhances ECAR in cancer cells . When using RTKN2 antibodies in this context, they are primarily employed for confirming successful manipulation of protein levels rather than direct metabolic measurements.

What are the key considerations when using RTKN2 antibodies in clinical or translational research?

When extending RTKN2 research to clinical applications:

• Tissue-specific validation:

  • Different antibody clones show variable performance across tissue types

  • For IHC applications, optimize antigen retrieval methods specifically for RTKN2:

    • TE buffer pH 9.0 is suggested for many tissues

    • Alternatively, citrate buffer pH 6.0 may be used with optimization

• Integrating with patient data:

  • RTKN2 expression correlates with TNM staging and lymphatic metastasis in NSCLC

  • Consider stratifying samples based on tumor subtypes and stages

  • Analyze correlations with patient survival and treatment response

• Standardization approaches:

  • Use tissue microarrays for consistent processing conditions

  • Implement digital pathology quantification to reduce subjective interpretation

  • Include appropriate control tissues within the same specimen block

• Combinatorial biomarker strategies:

  • Combine RTKN2 detection with other pathway components (NF-κB, Wnt/β-catenin)

  • Consider multiplexed immunofluorescence to analyze co-expression patterns

  • Correlate protein levels with transcript data when available

• Reporting standards:

  • Document antibody clone, catalog number, dilution, and incubation conditions

  • Report scoring methods and cut-off determination approaches

  • Include both representative positive and negative staining images